BR112017020689A2 - imunoconjugados em nanopartículas - Google Patents
imunoconjugados em nanopartículasInfo
- Publication number
- BR112017020689A2 BR112017020689A2 BR112017020689A BR112017020689A BR112017020689A2 BR 112017020689 A2 BR112017020689 A2 BR 112017020689A2 BR 112017020689 A BR112017020689 A BR 112017020689A BR 112017020689 A BR112017020689 A BR 112017020689A BR 112017020689 A2 BR112017020689 A2 BR 112017020689A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunoconjugates
- nanoparticulate
- diameter
- dls
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Silicon Compounds (AREA)
Abstract
a presente invenção refere-se a imunoconjugados em nanopartículas úteis para a terapêutica e/ou a diagnose. os imunoconjugados têm diâmetro (por exemplo, diâmetro médio) de não mais do que 20 nanômetros (por exemplo, quando medido por dispersão de luz dinâmica (dls) em solução aquosa, por exemplo, solução salina). em certas concretizações, os conjugados são nanopartículas à base de sílica com fragmentos de anticorpo de cadeia simples ligados a elas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562144278P | 2015-04-07 | 2015-04-07 | |
US201562151943P | 2015-04-23 | 2015-04-23 | |
PCT/US2016/026434 WO2016164578A1 (en) | 2015-04-07 | 2016-04-07 | Nanoparticle immunoconjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017020689A2 true BR112017020689A2 (pt) | 2018-06-26 |
Family
ID=55806803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017020689A BR112017020689A2 (pt) | 2015-04-07 | 2016-04-07 | imunoconjugados em nanopartículas |
Country Status (10)
Country | Link |
---|---|
US (3) | US10548989B2 (pt) |
EP (1) | EP3280454A1 (pt) |
JP (2) | JP6869187B2 (pt) |
KR (1) | KR20180002645A (pt) |
CN (2) | CN113876962A (pt) |
AU (2) | AU2016246737B2 (pt) |
BR (1) | BR112017020689A2 (pt) |
CA (1) | CA2980462C (pt) |
HK (1) | HK1250646A1 (pt) |
WO (1) | WO2016164578A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105307687A (zh) | 2013-03-15 | 2016-02-03 | 索隆-基特林癌症研究协会 | 多模态的基于二氧化硅的纳米粒子 |
CN113876962A (zh) * | 2015-04-07 | 2022-01-04 | 纪念斯隆-凯特琳癌症中心 | 纳米粒子免疫偶联物 |
CN108377643B (zh) | 2015-05-29 | 2021-09-21 | 纪念斯隆凯特琳癌症中心 | 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法 |
BR112018069133A2 (pt) | 2016-04-29 | 2019-01-22 | Univ Cornell | composições e métodos para penetração direcionada de partículas, distribuição, e resposta em tumores cerebrais malignos |
US11660354B2 (en) | 2016-11-30 | 2023-05-30 | Memorial Sloan Kettering Cancer Center | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof |
WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
KR102228571B1 (ko) * | 2017-02-09 | 2021-03-16 | 주식회사 메디폴리머 | 정신질환 또는 중추신경계 질환 치료용 약물전달 제형 |
WO2018217528A1 (en) * | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof |
CN111587115A (zh) * | 2018-01-12 | 2020-08-25 | 普罗林科斯有限责任公司 | 协同癌症治疗 |
JP2021521100A (ja) * | 2018-04-06 | 2021-08-26 | ノース カロライナ ステート ユニバーシティNorth Carolina State University | 癌免疫療法のためのチェックポイント阻害剤の細胞集団を介した送達 |
WO2019246591A1 (en) * | 2018-06-21 | 2019-12-26 | Codiak Biosciences, Inc. | Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering |
CN109490523A (zh) * | 2018-10-22 | 2019-03-19 | 北京纳晶生物科技有限公司 | 用于标记的纳米材料、核酸探针及核酸与纳米材料偶联的方法 |
KR102336120B1 (ko) * | 2019-06-05 | 2021-12-08 | 주식회사 엔이에스바이오테크놀러지 | 금 나노입자-앱타머 결합체를 기반으로 하는 항체 전달체 및 이의 제조 방법 |
JP2022547277A (ja) | 2019-09-16 | 2022-11-11 | エービーケー バイオメディカル インコーポレイテッド | 放射性微粒子及び非放射性微粒子の組成物 |
WO2021054490A1 (ko) * | 2019-09-18 | 2021-03-25 | 연세대학교 산학협력단 | 양친매성 고분자, 이를 포함하는 수분산성 금속나노입자 및 이의 제조방법 |
AU2020377966A1 (en) * | 2019-11-04 | 2022-05-19 | Cornell University | Ultrasmall nanoparticles and methods of making, using and analyzing same |
CN111906328B (zh) * | 2020-08-11 | 2022-10-25 | 苏州大学 | 一种177Lu标记的金纳米团簇及其制备方法和应用 |
CA3195153A1 (en) | 2020-10-27 | 2022-05-05 | Elucida Oncology, Inc. | Folate receptor targeted nanoparticle drug conjugates and uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5141648A (en) | 1987-12-02 | 1992-08-25 | Neorx Corporation | Methods for isolating compounds using cleavable linker bound matrices |
US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
JP2003514903A (ja) | 1999-11-24 | 2003-04-22 | イムノージェン インコーポレーテッド | タキサンを含有する細胞傷害薬とその治療への利用 |
US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
DK1507556T3 (en) | 2002-05-02 | 2016-09-12 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
KR20040106547A (ko) | 2002-05-15 | 2004-12-17 | 엔도사이트, 인코포레이티드 | 비타민-마이토마이신 공액체 |
US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US20060222595A1 (en) * | 2005-03-31 | 2006-10-05 | Priyabrata Mukherjee | Nanoparticles for therapeutic and diagnostic applications |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
WO2009045579A2 (en) * | 2007-06-14 | 2009-04-09 | The Regents Of The University Of California | Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics |
US20080317768A1 (en) * | 2007-06-21 | 2008-12-25 | Boeing Company | Bioconjugated nanoparticles |
AU2008308509B2 (en) * | 2007-10-04 | 2014-10-23 | Zymogenetics, Inc. | B7 family member zB7H6 and related compositions and methods |
CN104524590B (zh) | 2008-04-30 | 2019-06-21 | 伊缪诺金公司 | 交联剂和它们的用途 |
CA2744344A1 (en) * | 2008-11-26 | 2010-06-03 | National Research Council Of Canada | Antibody-targeted carrier for contrast agents |
PT3912643T (pt) | 2009-02-13 | 2023-01-12 | Immunomedics Inc | Imunoconjugados com uma ligação intracelular clivável |
CN102713612B (zh) * | 2009-07-02 | 2016-10-05 | 斯隆-凯特林癌症研究院 | 基于二氧化硅的荧光纳米颗粒 |
NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
SI3549963T1 (sl) * | 2010-04-15 | 2022-04-29 | Kodiak Sciences Inc. | Polimeri z visoko molekulsko maso, ki vsebujejo zwitterion |
CN105307687A (zh) * | 2013-03-15 | 2016-02-03 | 索隆-基特林癌症研究协会 | 多模态的基于二氧化硅的纳米粒子 |
CN113876962A (zh) | 2015-04-07 | 2022-01-04 | 纪念斯隆-凯特琳癌症中心 | 纳米粒子免疫偶联物 |
WO2018217528A1 (en) * | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Ultrasmall nanoparticles labeled with zirconium-89 and methods thereof |
-
2016
- 2016-04-07 CN CN202111317319.3A patent/CN113876962A/zh active Pending
- 2016-04-07 CA CA2980462A patent/CA2980462C/en active Active
- 2016-04-07 US US15/564,315 patent/US10548989B2/en active Active
- 2016-04-07 EP EP16718099.1A patent/EP3280454A1/en active Pending
- 2016-04-07 CN CN201680024624.4A patent/CN107735110B/zh active Active
- 2016-04-07 JP JP2017552058A patent/JP6869187B2/ja active Active
- 2016-04-07 AU AU2016246737A patent/AU2016246737B2/en active Active
- 2016-04-07 KR KR1020177031663A patent/KR20180002645A/ko active IP Right Grant
- 2016-04-07 WO PCT/US2016/026434 patent/WO2016164578A1/en active Application Filing
- 2016-04-07 BR BR112017020689A patent/BR112017020689A2/pt active Search and Examination
-
2018
- 2018-08-07 HK HK18110131.9A patent/HK1250646A1/zh unknown
-
2019
- 2019-11-26 AU AU2019271919A patent/AU2019271919B2/en active Active
- 2019-12-19 US US16/720,176 patent/US20200353096A1/en not_active Abandoned
-
2021
- 2021-02-01 JP JP2021014331A patent/JP7016975B2/ja active Active
-
2022
- 2022-10-07 US US17/961,761 patent/US20230037294A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018516854A (ja) | 2018-06-28 |
AU2016246737B2 (en) | 2019-11-21 |
JP2021073271A (ja) | 2021-05-13 |
CN107735110B (zh) | 2021-11-26 |
AU2019271919A1 (en) | 2019-12-19 |
JP6869187B2 (ja) | 2021-05-12 |
CN113876962A (zh) | 2022-01-04 |
US20230037294A1 (en) | 2023-02-09 |
US20200353096A1 (en) | 2020-11-12 |
KR20180002645A (ko) | 2018-01-08 |
CA2980462A1 (en) | 2016-10-13 |
HK1250646A1 (zh) | 2019-01-11 |
US20180133342A1 (en) | 2018-05-17 |
EP3280454A1 (en) | 2018-02-14 |
AU2019271919B2 (en) | 2021-10-28 |
AU2016246737A1 (en) | 2017-10-12 |
JP7016975B2 (ja) | 2022-02-07 |
US10548989B2 (en) | 2020-02-04 |
CN107735110A (zh) | 2018-02-23 |
CA2980462C (en) | 2023-08-01 |
WO2016164578A1 (en) | 2016-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017020689A2 (pt) | imunoconjugados em nanopartículas | |
BR112018073574A2 (pt) | conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização | |
BR112018008358A2 (pt) | ?composições e métodos para terapia relacionada à microbiota fecal? | |
CL2018002291A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados (divisional solicitud 201600221) | |
CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
BR102015017380A2 (pt) | dispositivo para a reticulação do tecido do olho, e, composição farmacêutica | |
BR112018013218A2 (pt) | derivado de acrilanilida, método de preparação e aplicação do mesmo na farmácia | |
CL2018000739A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma. | |
BR112015021134A2 (pt) | conjugados de fármaco e anticorpo | |
BR112015005779A2 (pt) | toner, revelador e aparelho de formação de imagem | |
BR112015020911A2 (pt) | anticorpo, uso de uma combinação e método de tratamento | |
AR104664A1 (es) | Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6) | |
BR112015004875A2 (pt) | formulações de anticorpo e seus usos | |
CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
BR112017026027A2 (pt) | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 | |
CO2019011640A2 (es) | Métodos y composiciones para la reducción de la inmunogenicidad | |
CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
BR112019012071A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de integrina | |
CL2014002975A1 (es) | Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2. | |
AR098168A1 (es) | Formulación estable de insulina glulisina | |
BR112018007703A2 (pt) | anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo | |
BR112018076639A2 (pt) | quimioterapias de combinação | |
BR112015014176A2 (pt) | associação de uma imagem de nuvem de pontos com um desenho de linhas de tubulação e aplicação de dimensões relativas à mesma | |
PE20151664A1 (es) | Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico | |
BR112017000312A2 (pt) | sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |